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Background: The molecular mechanism by which -conotoxin RegIIA inhibits 34, 32, and 7 nAChRs is unknown.
Results: Alanine scanning mutagenesis and molecular dynamic simulations of RegIIA revealed Asn11 and Asn12 confer
improved selectivity at 34 nAChR.
Conclusion:We synthesized the [N11A,N12A]RegIIA analog that selectively inhibits 34.
Significance: These findings could be used to develop 34-selective drugs to treat lung cancer.
Activation of the 34 nicotinic acetylcholine receptor
(nAChR) subtype has recently been implicated in the pathophysi-
ology of various conditions, including development and progres-
sion of lung cancer and in nicotine addiction. As selective 34
nAChR antagonists, -conotoxins are valuable tools to evaluate
the functional roles of this receptor subtype. We previously
reported the discovery of a new 4/7-conotoxin, RegIIA. RegIIA
was isolated from Conus regius and inhibits acetylcholine (ACh)-
evoked currents mediated by 34, 32, and 7 nAChR sub-
types. The current study used alanine scanning mutagenesis to
understand the selectivity profile of RegIIA at the 34 nAChR
subtype. [N11A]and [N12A]RegIIAanalogsexhibited3-foldmore
selectivity for the 34 than the 32 nAChR subtype. We also
report synthesis of [N11A,N12A]RegIIA, a selective 34 nAChR
antagonist (IC50 of 370 nM) that could potentially be used in the
treatment of lung cancer and nicotine addiction. Molecular
dynamics simulations of RegIIA and [N11A,N12A]RegIIA bound
to 34 and 32 suggest that destabilization of toxin contacts
with residues at the principal and complementary faces of 32
(3-Tyr92, Ser149, Tyr189, Cys192, and Tyr196;2-Trp57, Arg81, and
Phe119) may form themolecular basis for the selectivity shift.
Nicotinic acetylcholine receptors (nAChR)4 are ligand-gated
ion channels expressed in the central nervous system (CNS)
and peripheral nervous system (1). They are pentameric recep-
tors composed of a combination of subunits (2–10) and sub-
units (2–4). Heteromeric (for example, 32 and 42) and
homomeric isoforms (only7and9 subunits) ofnAChRsexhibit
diverse structural and functional heterogeneity (2). Their physio-
logical role in modulating pre- and post-synaptic transmission in
the CNS, and visceral and somatic sensory transmission in the
peripheral nervous system are well understood (3, 4).
nAChRs have been implicated in the pathophysiology of a
number of health conditions, including Alzheimer disease,
schizophrenia, tobacco addiction, and lung cancer (5). Our
understanding of isoform distribution and neurophysiological
roles of individual receptor subtypes in these conditions is lim-
ited by a lack of adequate isoform-specific probes (6).
An initial report suggesting that nAChRs may regulate
cancer cell growth (7) was followed by a number of studies
investigating the role of nAChRs in cancer development and
progression (reviewed in Ref. 8). Two studies identified tobac-
co-specific nitrosamines as potent nAChR agonists and inhib-
itors of cancer cell apoptosis (9). In addition, genome-wide
studies identified associations between lung cancer and several
single nucleotide polymorphisms within the gene cluster
encoding the 3, 5, and 4 nAChR subunits (10). Addition-
ally, activation of the 34 nAChR, a predominant subtype
expressed in sympathetic and parasympathetic neurons of
mammalian autonomic ganglia (11–13), is known to be associ-
ated with nicotine addiction and drug abuse (14, 15). However,
our understanding of the physiological relationship is limited.
Conotoxins are bioactive peptides isolated from the venom
of cone snails of the genus Conus (16). -Conotoxins are a spe-
cific class of short, disulfide-constrained peptides with a con-
served Cys-framework, CCXnCXmC. Xn and Xm represent the
number of amino acids and are used to subclassify peptides
such as 4/3, 4/4, and 4/7, which specifically target various
nAChR isoforms (17). Thus they represent excellent molecular
probes to elucidate the physiological roles of nAChR subtypes
in normal and disease states (18). The structural and functional
properties of a number of -conotoxins have been character-
ized (16–19). Although -conotoxins such as ImII and RgIA
exhibit selective inhibitory activity at 7 (20) and 910 (21)
nAChR subtypes, respectively, most known -conotoxins tar-
getmultiple nAChR subtypes (16, 17).-Conotoxin AuIB is the
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only known peptide that selectively targets the 34 nAChR
subtype albeit with low potency (IC50 2.5 M) (22, 23).
Mutagenesis experiments have become an important tool to
improve selectivity and potency of receptor inhibitors (see for
example, Ref. 24). Previously we reported the discovery and
isolation from Conus regius venom of the 4/7-conotoxin
RegIIA (25). RegIIA potently inhibits ACh-evoked currents of
34, 32, and 7 nAChR isoforms. Given the pathophysio-
logical association of the 34 nAChR subtype with various
disorders such as lung cancer and nicotine addiction, we have
now employed mutagenesis with the aim of improving the
selectivity profile of RegIIA. Using alanine scanning mutagen-
esis and modeling studies, we also identified critical -cono-
toxin RegIIA residues that interact with 32, 34, and 7
nAChR ACh-binding sites.
EXPERIMENTAL PROCEDURES
Peptide Synthesis—All of the peptide analogs were assembled
on rink amide methylbenzhydrylamine resin (Novabiochem;
0.7 mmol g1) using o-benzotriazole-N,N,N,N-tetramethylu-
ronium hexafluorophosphate (HBTU)-mediatedmanual solid-
phase peptide synthesis, with an in situ neutralization proce-
dure for N-(9-fluorenyl)methoxycarbonyl (Fmoc) chemistry.
Each cycle consisted of Fmoc deprotection with 20% piperidine
in dimethylformamide, followed by Fmoc amino acid coupling
using HBTU and N,N-diisopropylethylamine in dimethylfor-
mamide. A 2-fold excess of Fmoc amino acids was used in the
coupling reactions. All peptides were synthesized in globular
conformation (I-III and II-IV disulfide connectivity) through
incorporation of Fmoc-Cys acetamidomethyl (Acm)–OH at
positions 2 and 8 of the amino acid sequence (I-III disulfide
bond). The efficiency of the coupling reactions were checked
using the Kaiser Ninhydrin test.
Peptides were cleaved from the dried resin (0.4 g) by treat-
ment with 100ml of TFA, triisopropylsilane, and water as scav-
engers (95:2.5:2.5, TFA:triisopropylsilane:water, v/v/v). The
reaction was allowed to proceed at room temperature (20–
23 °C) for 2.5 h. The TFA was then evaporated, and the peptide
was precipitated with ice-cold ether, filtered, dissolved in 50%
buffer A/B (buffer A: H2O, 0.05% TFA; buffer B: 90% CH3CN,
10% H2O, 0.045% TFA) and lyophilized. Crude peptides were
purified by reversed phase-high performance liquid chroma-
tography (RP-HPLC) on a Phenomenex C18 column using a
gradient of 0–80% buffer B for 80 min and the elutant was
monitored at 215/280 nm. Unless otherwise stated, the same
conditions were used in subsequent purification steps. Electro-
spray-mass spectroscopy (ESI-MS) confirmed the molecular
mass of the fractions collected.
Fractions displaying the correct molecular mass for linear pep-
tide were pooled and lyophilized for oxidation. Linear peptides
were oxidized in two steps. First, they were dissolved in 0.1 M
NH4HCO3 (pH8.2) at a concentrationof 0.3mg/ml. Stirringover-
night at room temperature formed the II-IV disulfide bond. The
acetamidomethyl (Acm) protecting groups were stable under
these conditions. Second, iodine (0.01–0.1M)was added for 5min
at 37 °C, and excess iodinewas destroyed by adding sodiumascor-
bate. This formed the I-III disulfide bond. The oxidized peptides
were purified by RP-HPLC using a gradient of 0–80% buffer B
over 160 min. Analytical RP-HPLC and ESI-MS confirmed the
purity andmolecular mass of the synthesized peptides.
NMR Spectroscopy—Nuclear magnetic resonance (NMR)
data for all peptides were recorded on Bruker Avance 500- and
600-MHz spectrometers, with samples dissolved in 90% H2O,
10% D2O. Two-dimensional NMR experiments included
TOCSY (total correlation spectroscopy) and NOESY (nuclear
Overhauser effect spectroscopy) recorded at 280 K. Spectra
were analyzed using Topspin 1.3 (Bruker) and Sparky software.
Unless specified, spectra were recorded at pH 3.5.
Two-electrode Voltage Clamp Electrophysiological Record-
ings of nAChRs Expressed in Xenopus Oocytes—Stage V-VI
oocytes were harvested from mature female Xenopus laevis
anesthetized with 0.1% tricaine, following protocols approved
by the RMIT Animal Ethics Committee. RNA and Xenopus
oocytes were prepared, then nAChR subtypes were expressed
in oocytes as described previously (26). Briefly, cDNAs encod-
ing the rat3,2, and4 subunits, and human7 subunit were
subcloned into oocyte expression vector pT7TS and the 6/3
chimera plasmid was kindly provided by Dr.MichaelMcIntosh
(University ofUtah).mRNAcorresponding to each subunit was
prepared using the mMESSAGE mMACHINE Kit (Ambion,
Invitrogen). Oocytes were injected with 5 ng of cRNA for each
subtype in a 1:1 ratio. However, for the expression of 6/3
receptors, 15–20 ng of cRNA for each subunit was injected. The
injected oocytes were then incubated for 2–5 days at 18 °C in
ND96buffer (96mMNaCl, 2mMKCl, 1mMCaCl2, 1mMMgCl2,
and 5 mM HEPES, pH 7.4) supplemented with 50 mg/liter of
gentamicin and 100 g/units/ml of penicillin-streptomycin,
before recording. Membrane currents from Xenopus oocytes
were recorded at room temperature (20–23 °C), using a bath
solution of ND96 as described above. A two-electrode voltage
clamp (virtual ground circuit) with either a GeneClamp 500B
amplifier (Molecular Devices, Sunnyvale, CA) or an automated
work station with eight channels in parallel, including drug
delivery and online analysis (OpusXpressTM 6000A, Axon
Instruments Inc.) was used.
All recordings were made using voltage recording and cur-
rent-injecting electrodes were pulled from borosilicate glass
(GC150T-7.5, HarvardApparatus Ltd., Holliston,MA) and had
resistances of 0.3–1.5 M when filled with 3 M KCl. Oocytes
were voltage clamped at a holding potential of80mV. During
recordings, oocytes were perfused continuously at a rate of 2
ml/min, with ACh (200 M for 7 and 50 M for all other
nAChR subtypes) applied for 2 s at 2 ml/min. A 180- to 240-s
interval washout period was used between every ACh applica-
tion. The inhibitory effect of each peptide at the respective con-
centration represents the ratio of ACh-evoked peak amplitude
evoked before and following 300-s incubation with peptide.
Data were filtered at 10 Hz and sampled at 500 Hz (27).
Data Analysis—Concentration-response curves for antago-
nists were fitted by unweighted nonlinear regression to the
logistic equation,
Ex  Emax X
nH/XnH IC50
nH (Eq. 1)
where Ex is the response, X is the antagonist concentration,
Emax is the maximal response, nH is the slope factor, and IC50 is
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the antagonist concentration giving 50% inhibition of the max-
imal response. All electrophysiological data were pooled (n 
4–8 for each data point) and represent arithmetic mean S.E.
of the fit. Computation was done using GraphPad Prism 6.03
(GraphPad Software, Inc., La Jolla, CA).
Homology Modeling—Homology models of the extracellular
ligand-binding domain of rat (3)2(2)3 and (3)2(4)3
nAChRs bound to RegIIA or [N11A,N12A]RegIIA were con-
structed using the crystallographic coordinates of Aplysia cali-
fornica acetylcholine-binding protein, co-crystallized with the
double mutant -conotoxin PnIA[A10L,D14K] (Protein Data
Bank accession code 2BR8) (28) as a template. RegIIA and dou-
ble mutant peptides were modeled bound to the (	)()
receptor binding sites using the geometry of the PnIAmutant in
the acetylcholine-binding protein crystal structure as a tem-
plate. This provided a suitable 4/7 -conotoxin-bound confor-
mation of the receptor for subsequent molecular dynamics
(MD) simulations and analyses.
FIGURE 1. HPLC and ESI-MS profile of [N11A,N12A]RegIIA. A, an overlay of the analytical RP-HPLC traces for RegIIA (black), reduced and Acm-protected
[N11A,N12A]RegIIA (red), oxidized andAcm-protected [N11A,N12A]RegIIA (blue), and [N11A,N12A]RegIIA (green). Peptideswere analyzedwith a Phenomenex
C18 Jupiter 300 column (150
 2 mm) using a solvent gradient from 5 to 50% buffer B for 35 min. B, ESI-MS data of [N11A,N12A]RegIIA.
FIGURE2.SecondaryHshiftsofRegIIAandalanineanalogsat280K.The
secondary shift values of the peptide backbone (residues 2–12) for most of
the analogs correlate well with RegIIA.
Structure-Activity Relationship of-Conotoxin RegIIA
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Rat 3, 2, and 4 sequences were obtained from the Swiss-
Prot database (codes P04757, P12390, and P12392, respec-
tively), and aligned with the template sequence using the
ClustalW server. BLOSUM was used as the scoring matrix.
Using the multiple alignment as input, 10 models each of the
RegIIA-32, RegIIA-34, [N11A,N12A]RegIIA-32, and
[N11A,N12A]RegIIA-34 complexes were generated using
Modeler9v6 (29). The top ranking models were selected and
validated using PROCHECK (30). MD simulations were then
done on the top model of each of the four receptor complexes.
The overall fold of each homology model complex is qualita-
tively similar.
MD Simulations—Each of the four receptor complexes was
put in a separate cubic simulation box, with an edge length of
100 
 100 
 100 Å, and solvated with 27,229 (for 32) or
27,194 (34) TIP3P water molecules. To neutralize charge
and maintain an ionic concentration of 150 mM, 115 (for
32) or 88 (34) Na	 and 70 Cl ions were added to the
solvent. All simulations were performed using GROMACS ver-
sion 4.5.5 (31, 32), with CHARMM27 force-field version 2.0
(with cmap) (33).
Before undergoing MD simulations, the complexes were
energy minimized using the steepest descent algorithm and an
energy gradient convergence criterion of 0.01 kcal/mol/Å. All
FIGURE 3. Inhibition of nAChR subtypes expressed in Xenopus oocytes by RegIIA and alanine analogs. A, bar graph of inhibition of nAChR subtypes by
RegIIAand its analogs.B, two-wayanalysis of variance scatterplot illustrating the lossof activityof RegIIAanalogs (300nM) relative towild-typeRegIIAat various
nAChR subtypes. [H14A]RegIIA completely lost its activity at 32, 34, and 7 nAChRs. [N9A]RegIIA was more selective for the 32 subtype than RegIIA.
[N11A]RegIIA and [N12A]RegIIA selectivity for the 34 nAChR subtype significantly improved. All analogs, except [P13A]RegIIA, significantly lost activity at
the 7 nAChR subtype. ***, p 0.001; *, p 0.05; n 4–6. C, superimposed traces showing inhibition of 32 nAChR-mediated ACh-evoked currents by 100
nM RegIIA (i), [N11A]RegIIA (ii), and [N11A]RegIIA (iii). D, concentration-response curves for RegIIA (i), [N11A]RegIIA (ii) and [N12A]RegIIA (iii) inhibition of the
34 (black line,open symbols) and32nAChR subtypes (dash line, closed symbols). [N11A]RegIIA and [N12A]RegIIA shifted the curve to the right for the32
nAChR subtype, giving an IC50 value of 116 and 278 nM, respectively. All data represents mean S.E., n 4–6.
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MD simulations were performed using a constant particle
number, pressure, and temperature ensemble, with tempera-
ture maintained at 300 K using the v-rescale temperature cou-
pling algorithm (34), and pressuremaintained at 1 bar using the
Parrinello-Rahman pressure coupling algorithm (35). Time
steps of 2 fs were used to integrate all simulations.
Solvent equilibration simulations of 100 ps lengths were per-
formed. In these simulations, the non-hydrogen atoms of the
receptor and toxins were positionally restrained so the solvent
and ions could undergo motions to reach equilibrium from an
initially energetically unfavorable state, without disturbing the
protein. Subsequent simulations of all four complexes were
then performed with all atoms free of the system to undergo
dynamics.
To improve conformational sampling, we performed 10
independent simulations for each complex, using different ran-
dom seeds to assign initial particle velocities. Each simulation
was performed for 20 ns (i.e. 200 ns of trajectory per complex).
To reduce bias from initial homology model conformations, all
analyses were performed on the final 10 ns of the trajectories.
Unless indicated, all datawere taken as an average over the 10
independent simulations. Molecular graphics were produced
using VMD version 1.9.2 (36). All analyses were performed
using a combination of VMD, GROMACS analysis software
suite, and in-house scripts.
The interatomic contact difference plot (N) was calculated
by determining the total number of toxin contacts within 4.5 Å
of each receptor residue for wild-type andmutant RegIIA, aver-
aged over 10 independent simulations and both (	)()
interfaces (20 data points per receptor residue). To obtain N
values, the wild-type contact number was subtracted from that
of the double mutant.
RESULTS
Synthesis of RegIIA Analogs—We used an alanine scan
mutagenesis approach to elucidate the molecular mechanism
underlying inhibition of the 34 nAChR subtype by RegIIA.
This technique is well established, and in conjunction with
atomistic MD simulations, has enabled significant advances in
molecular pharmacology (see for example Refs. 37 and 38).
-Conotoxin RegIIA belongs to the 4/7 subclass having the
conserved Cys-framework CCXnCXmC. Due to its I-III and
II-IV disulfide connectivity, native RegIIA exhibits a classical
helical, globular structure (25). This globular conformation bal-
ances the shape, charge, and polarity of the peptide. As-cono-
toxins contain four cysteines there are two additional disulfide
isomers that can form during oxidative folding or disulfide
reshuffling, the ribbon (I-IV and II-III disulfide bonds) or bead
(I-II and III-IV disulfide bonds) isomers. Changes in the disul-
fide connectivity are reflected in the peptide conformation and
canhave a significant impact on-conotoxin potency and spec-
ificity at nAChRs (39, 40).
We used regioselective disulfide bond formation with Acm-
protected cysteine residues incorporated at positions 1 and 3,
and a two-step oxidation procedure, to produce the alanine
mutant peptides in a globular conformation (I-III and II-IV
disulfide bonds). The two-step oxidation process was con-
firmed by RP-HPLC, ESI-MS (Fig. 1), and two-dimensional
NMR. Fig. 2 show the negative 1H shift values between amino
acid positions 3 and 7 indicating the presence of an -helix
secondary structure.
AlanineMutagenesis Reveals Key Residues for RegIIA-nAChR
Activity—To understand the structure-activity relationship of
RegIIA at nAChRs, we tested loop 2 alanine analogs of RegIIA
(at a concentration of 300 nM) on 32, 34, and 7 nAChR
subtypes (Fig. 3A). [H14A]RegIIA showed complete loss of
activity at all three nAChR subtypes. All RegIIA analogs, except
[P13A]RegIIA, showed significantly reduced or complete loss
in activity at the7 nAChR subtype (Fig. 3B). [N9A]RegIIAwas
the only analog that showed no activity at the 34 and 7
nAChR subtype, whereas maintaining inhibition at 32
subtype. In contrast, we observed improved selectivity of
[N11A]RegIIA and [N12A]RegIIA for 34 with significantly
reduced (50%) inhibition of the 32 nAChR subtype (Fig. 3,
B and C). This was apparent from the shift in concentration-
response curves for [N11A]RegIIA and [N12A]RegIIA (Fig.
3D). IC50 values for [N11A]RegIIA and [N12A]RegIIA at the
32 nAChR subtype were 113.3 (95% Cl 70.6–181.8; nH 
0.9) and 255 nM (95% Cl 162.4–400.1; nH  1.1), respec-
tively. At the 34 nAChR subtype, the IC50 values were 51.6
nM (95% Cl 44.2–60.1; nH  2.0) and 112 nM (95% Cl 92.1–
136.2; nH1.7), respectively (Table 1).
[N11A,N12A]RegIIA: a Selective 34 nAChR Antagonist—
We synthesized the double mutant [N11A,N12A]RegIIA to
better understand the cumulative effect of the two residues on
nAChR activity. [N11A,N12A]RegIIA inhibited the 34
nAChR subtype with an IC50 of 370 nM (95% Cl 3.09–442.3;
nH 1.7), a 7-fold less potency than native RegIIA (Fig. 4).
However, at the 32 and 7 nAChR subtypes, potency
decreased by 1,000- (IC50 9.9 M) and 360-fold (IC50 21.5
M), respectively (Table 1). This indicates a decrease in selec-
tivity for the 32 and 7 nAChR subtypes. Furthermore, the
RegIIA double mutation led to a significant loss in activity at
6-containing receptors (Fig. 5). In comparison, wild-type
RegIIA potently inhibited 6/323 and 6/343 nAChR
subtypes, with IC50 values of 40 and 147 nM, respectively (Fig.
5). [N11A,N12A]RegIIA had 36-fold less potency at the
6/343 nAChR subtype than RegIIA (Fig. 5 and Table 1),
TABLE 1
RegIIA and analog inhibition of nAChR subtypes
IC50 values with 95% confidence interval (CI). Hill slope (nH) obtained from con-
centration-response curves for RegIIA and analogues at 32, 34, 7 and
6/343 nAChR subtypes. All data represent mean of n  4–6 experiments.
ND, not determined.
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and no activity at the 6/323 nAChR subtype at a concen-
tration of 10 M (Fig. 5). Inhibition of 34 by 100 nM RegIIA
and [N11A,N12A]RegIIA was reduced by greater than 40%,
with a 10-fold (30 to 300M) increase in theACh concentration
(data not shown). This shift in the concentration-response rela-
tionship clearly indicates that RegIIA and [N11A,N12A]RegIIA
are competitive antagonists of 34 nAChRs.
Key Toxin-Receptor Interactions Revealed byHomologyMod-
eling andMD Simulations—To understand the higher selectiv-
ity of [N11A,N12A]RegIIA for 34 than 32, we have used
homology models and atomistic MD simulations of wild-type
RegIIA and [N11A,N12A]RegIIAbound to either32 or34
(Fig. 6A). The initial homology models of wild-type RegIIA
bound to the two nAChR subtypes suggest that Asn11 and
Asn12 of RegIIA make contact predominantly with the 3(	)
face, although Asn11 also makes contact with 2-Arg81 and
Lys79 (4-Arg79 and Ile77) (Fig. 6B).
Because the interactions betweennAChRandRegIIA-Asn11/
Asn12 are similar for both 32 and 34, it is difficult to
rationalize the substantial selectivity change after doublemuta-
tion by employing “static” homology models alone. We there-
fore employed MD simulations, which take into account sol-
vent, temperature, and protein dynamics, to compare changes
in atomic contacts at the wild-type and mutated receptors. In
particular, we examined the effects of the [N11A,N12A] muta-
tion on contacts at sites distant from these positions (including
the () face, which differs substantially between 2 and 4),
which may help explain the basis of RegIIA selectivity.
Fig. 7 shows the change in number of toxin atoms (y axis)
residing within 4.5 Å of the molecular surface of each receptor
residue (x axis) at the (	)() interfaces (“Nprofiles”). This
is a measure of loss (negative values on the y axis) or gain (pos-
itive values) of toxin contacts as a result of the [N11A,N12A]
double mutation. The N profiles for 32 and 34 reveal
that the doublemutation generally reduces toxin-receptor con-
tacts at (	) face residues. However, the effect at the () face
is mixed, with reduced or increased number of contacts for
FIGURE 4. [N11A,N12A]RegIIA inhibition of 32 and 34 nAChR com-
paredwithwild-typeRegIIA inhibitionof these receptors.Concentration-
response curve for [N11A,N12A]RegIIA gave IC50 values of 370 nM and 9.9M
at 34 (Œ) and 32 (f) receptors, respectively, with an approximate
27-fold increased selectivity for 34 nAChR compared with RegIIA. Data
represent mean S.E., n 4–6.
FIGURE 5. [N11A,N12A]RegIIA inhibition of 6/323 and 6/343 nAChR compared with wild-type RegIIA inhibition of these receptors. A,
superimposed traces showing ACh-evoked current inhibition of 6/323 and 6/343 nAChR subtypes by RegIIA and [N11A,N12A]RegIIA. B, wild-type
RegIIA was active at 6-containing receptors with IC50 values of 40 and 147 nM at 6/323 () and 6/343 (E) receptors, respectively. Concentration-
response curve for [N11A,N12A]RegIIA gave an IC50 value of 5.1Mat6/343 (F), with an approximate 35-fold decrease in potency comparedwith RegIIA.
[N11A,N12A]RegIIA showed no activity at 6/323 () when tested at a concentration of 10 M. Data represents mean S.E., n 3–6.
Structure-Activity Relationship of-Conotoxin RegIIA
1044 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 290•NUMBER 2•JANUARY 9, 2015
 at UQ Library on October 25, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
different residues. As expected, mutation of Asn11 and Asn12
leads to decreased contact with receptor residues in the imme-
diate proximity of these (RegIIA) positions. Contact between
the Asn11 position with 3-Tyr196/2-Arg81 (4-Arg79), and
the Asn12 position with 3-Cys192, are reduced compared with
that of wild-type RegIIA (Fig. 6B).
The [N11A,N12A] mutation also markedly reduces toxin-
receptor contacts at regions distant from themutation sites. Of
particular interest and to explain the selectivity of the mutant
for 34, are receptor residues with substantially fewer toxin
contacts for 32 than 34 nAChR subtypes. Some of the
pairwise interactions involving these residues are illustrated in
Fig. 6C and are also marked with asterisks in Fig. 7. The most
prominent residues include 3-Tyr92, Ser149, Tyr189, Cys192,
and Tyr196 at the principal face, and 2-Trp57 (4-Trp55) and
2-Phe119 (4-Gln117) at the complementary face. These resi-
dues may be essential for RegIIA inhibition of 32. In partic-
ular, the marked loss of contact at 3-Cys192 in both 32 and
34 nAChR subtypes is consistent with similar observations
from previous studies of -conotoxin analogs and modifica-
tions. van Lierop et al. (41) showed dicarba modification of the
C2-C8 disulfide bond in Vc1.1 resulted in loss of activity at
910. Their MD simulations showed reduced contact
between the modified toxin and Cys-loop disulfide atoms.
Grishin et al. (38) found [F9A]AuIB lost its activity at34with
the MD simulations showing reduced contact between the
toxin and Cys-loop sulfur atoms due to this mutation. Our cur-
rent data supports the crucial role of Cys-loop sulfur atoms in
conotoxin inhibition of neuronal nAChRs.
Doublemutation also caused a loss of contact betweenAsn9/
Pro6 and 2-Trp57, whereas slightly increasing the contact
between Asn9/Pro6 and the homologous position at 4-Trp59
(Fig. 7). This, in addition to functional data for [N9A]RegIIA
showing complete loss in activity at 34 (Fig. 3), suggests
interaction betweenAsn9 and/4-Trp59might be important for
inhibition of the 34 subtype. This loss of toxin contact at
32, but not 34, may also contribute to the marked selec-
tivity change of the double mutant [N11A,N12A]RegIIA
toward the 34 nAChR subtype.
DISCUSSION
Since the discovery, in the worm-hunting cone snail Conus
imperialis, of -conotoxin ImI and its action on neuronal
nAChRs, numerous -conotoxins have been identified and
functionally characterized (16–19). A number of peptides have
been identified from the venom ofC. regius, aWestern Atlantic
worm-hunting cone snail species. These peptides belong to var-
ious superfamilies with eight being part of the A-superfamily
that is distinguished by cysteine framework I (42). The cono-
toxin composition of C. regius venom is clinically relevant
because it contains the -conotoxin RegIe and RegIIA both of
which have been identified as potential therapeutics. RgIA (free
FIGURE 6.Homologymodel andMDsimulation of RegIIA bound to32.
A, illustration of the initial structure (homologymodel) of RegIIA toxin bound
to the presumed inter-subunit C-loop pockets are shown in yellow. B, MD
simulation snapshot (at 20 ns) of RegIIA bound with 32 showing interac-
tions between Asn11, Asn12 and receptor residues at the 3(	) and 2()
faces; C, and of pairwise interactions that are substantially reduced at 32
comparedwith 34 after the [N11A,N12A]mutation. Conotoxin side chains
of interest are in licorice form. Receptor side chains are shown as ball and
stick. Atoms are color coded as: C cyan, H white, N blue, O red, and
S yellow.
FIGURE 7. Change in number of toxin atoms (N) that lie within 4.5 Å of
receptor residues (x axis) due to [N11A,N12A] double mutation of
RegIIA. Asterisks indicate residues with substantially fewer contacts for32
compared with 34. Residues from the 2 subunit are shown on the x axis.
Data from 34 is at the homologous positions. Error bars are mean  S.E.
calculatedover(	)/() interfaces for 10 independent simulations (20data
points in total).
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carboxyl C terminus form of [O6P]RegIe) selectively targets
pain transmission by modulation of the 910 nAChR subtype
and high voltage-activated N-type calcium channel currents,
via GABAB receptor activation (43). -Conotoxin RegIIA
potently inhibits activity of the 34 nAChR subtype (25) that
has been implicated in the pathophysiology of lung cancer.
RegIIA exhibits homology with a number of peptides (Table
2) having a conserved SHPA sequence in loop 1 and a NNP
motif in loop 2. The Ser and Pro residues of the SHPAmotif are
highly conserved in peptides of different subclasses that inhibit
various nAChR subtypes (Table 2). Sequence variations in loop
2 contribute to the unique nAChR subtype selectivity of
-conotoxins (44). However, the NNP motif is conserved in
peptides such as -conotoxins OmIA, EpI, PnIA, TxIA, and
ArIB that specifically inhibit 32 and 7 nAChR subtypes
(16). This observation is consistent with our finding that ala-
ninemutation of theNNPmotif of RegIIA significantly affected
inhibition at 32 and 7 nAChR subtypes (Fig. 3A). Alanine
mutations at other positions provided further information
about the structure-function relationship between -conotox-
ins andneuronal nAChRs.Asparagine (RegIIApositionnine) to
alaninemutation completely abolished inhibition of the 7 and
34 nAChRs.
The marked shifts in selectivity observed by the analogs
for either 32 or 34 subtype is intriguing given that both
receptors share a common principal subunit face at the pre-
sumed conotoxin binding site (Fig. 6A). Previous x-ray studies
of -conotoxin-acetylcholine-binding protein complexes, with
support from synthetic analogs, have improved our understand-
ing of ligand-receptor interactions (45–47). The extracellular
N-terminal domains of the 2 and 4 nAChR subunits bind
-conotoxins and exhibit 70% sequence homology. RecentMD
simulation studies also reveal well preserved structural topol-
ogy of 32 and 34 nAChRs. However, the ACh-binding
pocket interface between the  and  subunits was larger in
32 than 34 nAChR subtypes (48). Even though, both
Asn11 and Asn12 primarily interact with the 3(	) interface,
this difference could explain the shift in selectivity of [N11A]
and [N12A]RegIIA for 34 over 32.
Our findings are also supported by data from a recentmolec-
ular docking study of -conotoxin GIC with human 32 and
34 nAChR subtypes. The study revealed all three subunits
have residues that interact with GIC (3 subunit: Tyr92, Tyr150,
Tyr189, and Tyr196; 2 subunit: Trp57, Val111, Phe119, and
Leu121; and 4 subunit: Trp57, Ile111, Leu119 (Gln119 in rat 4)
and Leu121). Interestingly, the 3-Tyr196 and 2-Phe119 resi-
dues of the 32-GIC model were more closely located than
the 3-Tyr196 and 4-Leu119 residues of the 34-GIC model
(48). A comprehensive receptor mutagenesis study of the vari-
ous -conotoxins (MII, GID, and PnIA) that inhibit the 32
nAChR subtype indicates that the 2 subunit pharmacophore
comprising Thr59, Glu61, Val111, Phe119, and Leu121 residues,
also has a significant role in ligand binding (49). It is important
to note that, whereas both of the above studies identified similar
residues interacting with the conotoxins, increasing literature
on the pharmacological difference between rat and human
nAChR receptors is emerging (50, 51). The current study was
carried out using rat nAChR subunit clones, however, the activ-
ity of RegIIA and [N11A,N12A]RegIIA may differ at human
nAChR subtypes.
The selective 34 antagonist, AuIB, expanded our knowl-
edge of the distribution and physiological functions of this
nAChR subtype in various tissues, including dopaminergic sig-
naling in medial habenula (52), glutamatergic neurotransmis-
sion in cardiac vagal neurons (53), and keratinocyte chemoki-
nesis (54). However, the low potency of AuIB at 34 and its
off-target effect on Cav2.2 channel modulation via GABAB
receptor activation has hampered its use in in vivo studies.
Recent studies in development of selective and potent 34
antagonists led to the discovery and synthesis of two novel
TABLE 2
Sequence alignment of -conotoxins targeting various nAChR subtypes
a Amino acids homologous to RegIIA are labeled with a grey background. The conserved cysteine framework is highlighted in yellow. * indicates an amidated C terminus; up
free carboxyl C terminus; and # presence of additional subunits.
b Peptides inhibiting the 34 nAChR subtype and their corresponding IC50 values are shown.
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-conotoxins: TxID, a novel 4/6-conotoxin from Conus tex-
tile that potently blocks 34 (IC50  12.5 nM) (55) and
TP-2212-59, a synthetic analog of 4/4-conotoxin BuIA
(IC50 2.3 nM) (56). Although both peptides are potent inhib-
itors of the 34 nAChR subtype, TxID also inhibits 6/34
with only 7.5-fold less potency (IC50  94.1 nM) (55) and the
activity of TP-2212-59 at other nAChR subtypes such as
6-containing receptors is yet to be tested (56).
We report the successful synthesis of [N11A,N12A]RegIIA,
an 34 nAChR subtype-selective antagonist. [N11A,N12A]-
RegIIA is4-fold more potent than AuIB and could be used to
decipher the physiological role of 34 nAChR in pathological
states. MD simulations reveal a direct loss in pairwise contacts
between positions 11 and 12 and the principal face of the recep-
tor, including destabilization in other toxin-receptor contacts
at the complementary face. This is qualitatively consistent with
the 1000-fold decrease in [N11A,N12A]RegIIA inhibition of
the 32 nAChR subtype. Our homologymodels andMD sim-
ulations also suggest that at the2 subunit, Asn11 is close to two
basic residues (2-Arg81 and Lys79); whereas at the 4 subunit,
Asn11 is close to one basic (4-Arg79) and one non-polar resi-
due (4-Ile77). This has implications for rational toxin modifi-
cation. Based on the receptor environment surrounding Asn11,
it is possible that a N11K mutant would enhance selectivity for
34, because a Lys at position 11 would introduce electro-
static repulsionwith2-Arg81 and2-Lys79. Therewould likely
also be a reduction in affinity at 34. However, the repulsion
between N11K and 4-Arg79 might be partially offset by favor-
able contacts between the CH2 groups of N11K and 4-Ile77.
Further efforts to examine and optimize the selectivity of
RegIIA are presently ongoing.
Our study increases understanding of the interactions of
RegIIA with various nAChR subtypes. It also identifies key res-
idues such as Asn9, Asn11, andAsn12 involved in toxin-receptor
interaction. This information will be valuable in the design and
development of potent, 34-selective drugs to treat lung can-
cer and nicotine addiction.
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